Changzhou Sifary Medical Technology Co., Ltd, a China-based platform for the globalization of oral medical instruments, has reportedly raised “hundreds of millions” of renminbi in a Series B financing round. The funding was led by GF Xinde Investment, with contributions from Motianshi Investment and Youshuo Venture Capital. The proceeds will be used to accelerate the implementation of existing pipelines and the layout of its high-value medical consumables.
Company Overview and Growth
Founded in 2016, Sifary Medtech has launched more than 20 products and established a business presence in 141 countries worldwide. Despite the challenges posed by the COVID-19 pandemic, the company has achieved a compound growth rate in excess of 100% over the last three years. This rapid growth underscores Sifary Medtech’s commitment to innovation and its ability to expand its market reach globally.
Future Outlook
The Series B financing round positions Sifary Medtech to further enhance its global footprint and accelerate the development of its high-value medical consumables. With robust financial backing and a proven track record of growth, Sifary Medtech is poised to make a significant impact in the medical instrument sector. The company’s ongoing efforts to expand its product offerings and market presence highlight its dedication to improving healthcare outcomes through innovative solutions.-Fineline Info & Tech
